Cargando…

Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS

ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and coupl...

Descripción completa

Detalles Bibliográficos
Autores principales: McClenaghan, Conor, Mukadam, Maya A, Roeglin, Jacob, Tryon, Robert C, Grabner, Manfred, Dayal, Anamika, Meyer, Gretchen A, Nichols, Colin G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245035/
https://www.ncbi.nlm.nih.gov/pubmed/37154692
http://dx.doi.org/10.15252/emmm.202216883
_version_ 1785054774818766848
author McClenaghan, Conor
Mukadam, Maya A
Roeglin, Jacob
Tryon, Robert C
Grabner, Manfred
Dayal, Anamika
Meyer, Gretchen A
Nichols, Colin G
author_facet McClenaghan, Conor
Mukadam, Maya A
Roeglin, Jacob
Tryon, Robert C
Grabner, Manfred
Dayal, Anamika
Meyer, Gretchen A
Nichols, Colin G
author_sort McClenaghan, Conor
collection PubMed
description ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and couple cellular metabolism to excitability. AIMS individuals show fatigability, muscle spasms, and cardiac dysfunction. We found reduced exercise performance in mouse models of AIMS harboring premature stop codons in ABCC9. Given the roles of K(ATP) channels in all muscles, we sought to determine how myopathy arises using tissue‐selective suppression of K(ATP) and found that LoF in skeletal muscle, specifically, underlies myopathy. In isolated muscle, SUR2 LoF results in abnormal generation of unstimulated forces, potentially explaining painful spasms in AIMS. We sought to determine whether excessive Ca(2+) influx through Ca(V)1.1 channels was responsible for myopathology but found that the Ca(2+) channel blocker verapamil unexpectedly resulted in premature death of AIMS mice and that rendering Ca(V)1.1 channels nonpermeable by mutation failed to reverse pathology; results which caution against the use of calcium channel blockers in AIMS.
format Online
Article
Text
id pubmed-10245035
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102450352023-06-08 Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS McClenaghan, Conor Mukadam, Maya A Roeglin, Jacob Tryon, Robert C Grabner, Manfred Dayal, Anamika Meyer, Gretchen A Nichols, Colin G EMBO Mol Med Articles ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and couple cellular metabolism to excitability. AIMS individuals show fatigability, muscle spasms, and cardiac dysfunction. We found reduced exercise performance in mouse models of AIMS harboring premature stop codons in ABCC9. Given the roles of K(ATP) channels in all muscles, we sought to determine how myopathy arises using tissue‐selective suppression of K(ATP) and found that LoF in skeletal muscle, specifically, underlies myopathy. In isolated muscle, SUR2 LoF results in abnormal generation of unstimulated forces, potentially explaining painful spasms in AIMS. We sought to determine whether excessive Ca(2+) influx through Ca(V)1.1 channels was responsible for myopathology but found that the Ca(2+) channel blocker verapamil unexpectedly resulted in premature death of AIMS mice and that rendering Ca(V)1.1 channels nonpermeable by mutation failed to reverse pathology; results which caution against the use of calcium channel blockers in AIMS. John Wiley and Sons Inc. 2023-05-08 /pmc/articles/PMC10245035/ /pubmed/37154692 http://dx.doi.org/10.15252/emmm.202216883 Text en © 2023 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
McClenaghan, Conor
Mukadam, Maya A
Roeglin, Jacob
Tryon, Robert C
Grabner, Manfred
Dayal, Anamika
Meyer, Gretchen A
Nichols, Colin G
Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title_full Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title_fullStr Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title_full_unstemmed Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title_short Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
title_sort skeletal muscle delimited myopathy and verapamil toxicity in sur2 mutant mouse models of aims
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245035/
https://www.ncbi.nlm.nih.gov/pubmed/37154692
http://dx.doi.org/10.15252/emmm.202216883
work_keys_str_mv AT mcclenaghanconor skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT mukadammayaa skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT roeglinjacob skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT tryonrobertc skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT grabnermanfred skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT dayalanamika skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT meyergretchena skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims
AT nicholscoling skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims